Nasus Pharma Ltd.
NSRXHealthcare|Medical - Pharmaceuticals|IL
$2.82
-0.09 (-3.09%)
DCF Value
$0.06
Tangible Book / Share
$0.99
Cash / Share
$1.07
Financials
Financial Snapshot
Market Cap
$24.3M
Enterprise Value
$16.6M
Revenue (TTM)
$0.00
Net Income (TTM)
-$10.9M
Cash & Investments
$11.8M
Net Cash
$11.7M
Free Cash Flow (TTM)
-$3.4M
Operating CF (TTM)
-$3.4M
Debt/Equity
0.01
Cash Runway & Burn Rate
Cash on Hand
$11.8M
Quarterly Burn
$839.5K
Monthly Burn
$279.8K
Est. Runway
~14.1 quarters
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Cash & Investments | $154.0K | $193.0K | $284.0K | $4.3M | $11.8M | |
| Operating Cash Flow | -$1.2M | -$1.0M | -$665.0K | -$4.9M | -$3.4M | |
| Free Cash Flow | -$1.2M | -$1.0M | -$665.0K | -$4.9M | -$3.4M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | -$14.0K | -$5.6K | |
| Financing Cash Flow | $1.2M | $1.1M | $770.0K | $8.9M | $7.1M |
R&D Spending
R&D (TTM)
$4.6M
R&D Intensity
—
R&D Growth vs Prior
+106.4%
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $1.1M | $567.0K | $335.0K | $2.2M | $4.6M | |
| SG&A | $926.0K | $580.0K | $743.0K | $2.7M | $6.1M |
Income Statement
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D | $1.1M | $567.0K | $335.0K | $2.2M | $4.6M | |
| SG&A | $926.0K | $580.0K | $743.0K | $2.7M | $6.1M | |
| Operating Income | -$2.0M | -$1.1M | -$1.1M | -$4.9M | -$10.7M | |
| Interest Expense | $18.0K | $49.0K | $29.0K | $0.00 | $0.00 | |
| Pretax Income | -$2.2M | -$1.0M | -$1.6M | -$5.8M | -$10.9M | |
| Net Income | -$1.7M | -$1.1M | -$1.5M | -$5.9M | -$10.9M | |
| EPS (Diluted) | -0.19 | -0.12 | -0.17 | -0.72 | -1.03 | |
| EBITDA | -$2.1M | -$956.0K | -$1.5M | -$4.9M | -$7.2M | |
| Shares Out. (M) | 9.06 | 9.06 | 9.06 | 8.01 | 11.07 |
Balance Sheet
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $154.0K | $193.0K | $284.0K | $1.2M | $7.8M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $3.0M | $4.0M | |
| Total Current Assets | $417.0K | $444.0K | $457.0K | $4.9M | $12.3M | |
| Total Assets | $417.0K | $444.0K | $717.0K | $5.0M | $12.4M | |
| Total Current Liabilities | $3.2M | $4.2M | $3.9M | $2.2M | $1.4M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $3.2M | $4.2M | $3.9M | $2.2M | $1.5M | |
| Stockholders' Equity | -$2.8M | -$3.8M | -$3.2M | $2.8M | $11.0M | |
| Retained Earnings | -$10.1M | -$11.1M | -$12.7M | -$18.5M | -$24.5M |
Cash Flow Statement
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.2M | -$1.0M | -$665.0K | -$4.9M | -$3.4M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | -$14.0K | -$5.6K | |
| Free Cash Flow | -$1.2M | -$1.0M | -$665.0K | -$4.9M | -$3.4M | |
| Investing Cash Flow | -$160.0K | $0.00 | $0.00 | -$3.0M | -$1.2M | |
| Financing Cash Flow | $1.2M | $1.1M | $770.0K | $8.9M | $7.1M | |
| Issuance of Stock | $3.0K | $0.00 | $0.00 | $8.5M | $7.0M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $1.5M | $1.1M | $1.0M | $435.0K | $31.4K | |
| Stock Based Comp. | $23.0K | $39.0K | $10.0K | $447.0K | $513.00 | |
| Net Change in Cash | -$143.0K | $39.0K | $101.0K | $980.0K | $2.6M |
Dilution Tracker
Shares Outstanding
9M
5-Year Share Growth
-11.6%
Stock Issuance (TTM)
$7.0M
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Shares Out. (M) | 9.06 | 9.06 | 9.06 | 8.01 | 11.07 | |
| Change vs Prior % | — | 0.0% | 0.0% | -11.6% | 38.2% | |
| Stock Issuance | $3.0K | $0.00 | $0.00 | $8.5M | $7.0M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $23.0K | $39.0K | $10.0K | $447.0K | $513.00 |
Margins & Profitability
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| ROE % | 61.4% | 27.7% | 47.7% | -211.6% | -158.8% | |
| ROA % | -410.3% | -236.7% | -213.7% | -117.0% | -87.8% | |
| ROIC % | 168.3% | 85.6% | 76.5% | -169.9% | -96.5% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Income | 0.0% | 43.8% | 6.0% | -354.9% | |
| Net Income | 0.0% | 38.6% | -45.8% | -282.2% | |
| EPS (Diluted) | 0.0% | 36.8% | -41.7% | -323.5% | |
| Operating Cash Flow | 0.0% | 15.0% | 35.4% | -639.5% | |
| Free Cash Flow | 0.0% | 15.0% | 35.4% | -641.7% | |
| R&D Expense | 0.0% | -49.2% | -40.9% | 567.8% | |
| SG&A Expense | 0.0% | -37.4% | 28.1% | 259.0% | |
| Total Assets | 0.0% | 6.5% | 61.5% | 597.9% | |
| Book Value / Share | 0.0% | -36.3% | 15.4% | 197.5% | |
| Debt | 0.0% | 56.3% | -26.7% | -93.5% | |
| Diluted Shares | 0.0% | 0.0% | 0.0% | -11.6% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B2.84
EV/EBITDAAt Loss
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$0.06
Tangible Book / Share
$0.99
Net Current Assets / Share
$1.26
Graham Net-Net
$0.94
Cash / Share
$1.07
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| P/E Ratio | -43.42 | -68.75 | -48.53 | -12.71 | -2.75 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | -26.84 | -19.68 | -23.27 | 26.48 | 2.84 | |
| EV/EBITDA | -35.69 | -80.55 | -50.07 | -14.72 | -2.31 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
5.52
Safe
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $3.5M |
| Net Income | -$9.1M | -$8.8M | -$5.2M |
| EPS | $-1.13 | $-1.10 | $-0.65 |
| # Analysts (EPS) | 2 | 2 | 1 |